Rankings
▼
Calendar
JAZZ Q4 2016 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$11B
Q4 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$397M
Gross Profit
$363M
91.5% margin
Operating Income
$166M
41.7% margin
Net Income
$117M
29.4% margin
EPS (Diluted)
$1.91
QoQ Revenue Growth
+6.0%
Cash Flow
Operating Cash Flow
$181M
Free Cash Flow
$179M
Stock-Based Comp.
$24M
Balance Sheet
Total Assets
$4.8B
Total Liabilities
$2.9B
Stockholders' Equity
$1.9B
Cash & Equivalents
$366M
Revenue Segments
Xyrem
$291M
74%
Erwinaze And Erwinase
$57M
14%
Defitelio
$30M
8%
Other Products
$8M
2%
Prialt
$6M
2%
Psychiatry
$3M
1%
Geographic Segments
UNITED STATES
$363M
92%
Europe
$27M
7%
Other Countries
$7M
2%
← FY 2016
All Quarters
Q1 2017 →
